Gold prices slip slightly after recent gains; U.S. data eyed
On Monday, BTIG analysts reiterated a Buy rating and maintained a $37.00 price target for Liquidia Technologies stock (NASDAQ:LQDA), which has shown strong momentum with a 33% gain over the past six months. According to InvestingPro data, analyst targets for LQDA range from $13 to $41, reflecting varied outlooks on the company’s potential. This decision follows recent legal developments that were announced Friday evening, which have been seen as reducing risks for the company.
The analysts noted that their estimates are currently under review after what they referred to as a significant de-risking event. With a current ratio of 2.93, InvestingPro data shows Liquidia maintains strong liquidity to navigate its operations. They highlighted that there are no known ongoing lawsuits posing immediate injunctive risks to Liquidia’s YUTREPIA product. The judge overseeing the ’782 lawsuit considered the merits of the underlying case in his decision on United Therapeutics (NASDAQ:UTHR)’ temporary restraining order and preliminary injunction request, which BTIG believes could lead to a favorable final judgment for Liquidia.
In May 2024, a preliminary injunction request was denied in the ’327 lawsuit in Delaware, with specific commentary on the merits of United Therapeutics’ underlying lawsuit. United Therapeutics is now the defendant in a lawsuit initiated by Liquidia, which alleges infringement of Liquidia’s ’494 patent. This patent protects dosing between 100mcg and 300mcg per session and YUTREPIA’s differentiated titration window.
BTIG is scheduled to host a webcast call with Dr. Nicholas Kolaitis, a Pulmonary Hypertension Specialist at UCSF, on Tuesday, June 3, at 10 a.m. ET. The call aims to review the evolving treatment landscape. Interested parties are encouraged to contact their BTIG representative for access. For deeper insights into Liquidia’s financial health and growth prospects, including its projected 179% revenue growth for FY2025, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Liquidia Technologies has received a series of positive analyst updates following the FDA approval of its product, Yutrepia, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Raymond (NSE:RYMD) James raised its price target for Liquidia to $33, citing confidence in Yutrepia’s market potential. H.C. Wainwright followed suit, increasing its target to $35, highlighting the product’s dosing flexibility and potential for significant market penetration. Scotiabank (TSX:BNS) also adjusted its target to $37, emphasizing Liquidia’s comprehensive patient access programs and the anticipated revenue growth from Yutrepia’s launch. Additionally, BTIG raised its price target to $37, reflecting expectations for Yutrepia to gain traction and the company’s profitability prospects within three to four quarters. Wells Fargo (NYSE:WFC) increased its target to $23, maintaining an Overweight rating and noting Liquidia’s successful navigation of past regulatory and legal challenges. Analysts generally express optimism about Liquidia’s strategic positioning and the potential impact of Yutrepia in the market. These developments indicate a strong outlook for Liquidia as it advances its commercialization efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.